<ENAMEX TYPE="ORGANIZATION">G.D. Searle & Co.</ENAMEX> said the <ENAMEX TYPE="ORGANIZATION">Food and Drug Administration</ENAMEX> approved the sale of <ENAMEX TYPE="ORGANIZATION">Kerlone</ENAMEX>, a hypertension drug developed by a joint venture between <ENAMEX TYPE="ORGANIZATION">Searle</ENAMEX> and a French concern.
<ENAMEX TYPE="PERSON">Searle</ENAMEX>, a unit of <ENAMEX TYPE="ORGANIZATION">Monsanto Co.</ENAMEX>, said the ``beta-blocker'' high-blood-pressure drug Kerlone is the first product to reach the market through <ENAMEX TYPE="ORGANIZATION">Lorex Pharmaceuticals</ENAMEX>, the <ENAMEX TYPE="LOCATION">U.S.</ENAMEX> company jointly owned by <ENAMEX TYPE="PERSON">Searle</ENAMEX> and <ENAMEX TYPE="PERSON">Synthelabo</ENAMEX>, a French pharmaceutical concern owned by <ENAMEX TYPE="LOCATION">France</ENAMEX>'s <ENAMEX TYPE="ORGANIZATION">L'Oreal S.A.</ENAMEX>
